← Eichor
Study identifier: NCT06769113 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy

Condition: Esophageal Cancer  ·  Sponsor: Shanghai Henlius Biotech

PhasePhase 2
Planned participants102
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Jinming Yu, Dr.  ·  0531-67626971  ·  sdyujinming@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shandong Cancer HospitalJinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06769113